217 related articles for article (PubMed ID: 21567441)
1. Complementary vascular and matrix regulatory pathways underlie the beneficial mechanism of action of sorafenib in liver fibrosis.
Thabut D; Routray C; Lomberk G; Shergill U; Glaser K; Huebert R; Patel L; Masyuk T; Blechacz B; Vercnocke A; Ritman E; Ehman R; Urrutia R; Shah V
Hepatology; 2011 Aug; 54(2):573-85. PubMed ID: 21567441
[TBL] [Abstract][Full Text] [Related]
2. Hepatic and HSC-specific sorafenib effects in rats with established secondary biliary cirrhosis.
Hennenberg M; Trebicka J; Kohistani Z; Stark C; Nischalke HD; Krämer B; Körner C; Klein S; Granzow M; Fischer HP; Heller J; Sauerbruch T
Lab Invest; 2011 Feb; 91(2):241-51. PubMed ID: 20921950
[TBL] [Abstract][Full Text] [Related]
3. Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats.
Mejias M; Garcia-Pras E; Tiani C; Miquel R; Bosch J; Fernandez M
Hepatology; 2009 Apr; 49(4):1245-56. PubMed ID: 19137587
[TBL] [Abstract][Full Text] [Related]
4. New insights into the antifibrotic effects of sorafenib on hepatic stellate cells and liver fibrosis.
Wang Y; Gao J; Zhang D; Zhang J; Ma J; Jiang H
J Hepatol; 2010 Jul; 53(1):132-44. PubMed ID: 20447716
[TBL] [Abstract][Full Text] [Related]
5. Sorafenib targets dysregulated Rho kinase expression and portal hypertension in rats with secondary biliary cirrhosis.
Hennenberg M; Trebicka J; Stark C; Kohistani AZ; Heller J; Sauerbruch T
Br J Pharmacol; 2009 May; 157(2):258-70. PubMed ID: 19338580
[TBL] [Abstract][Full Text] [Related]
6. Combination of sorafenib and gadolinium chloride (GdCl3) attenuates dimethylnitrosamine(DMN)-induced liver fibrosis in rats.
Liu C; Yang Z; Wang L; Lu Y; Tang B; Miao H; Xu Q; Chen X
BMC Gastroenterol; 2015 Nov; 15():159. PubMed ID: 26572488
[TBL] [Abstract][Full Text] [Related]
7. Sorafenib attenuates the portal hypertensive syndrome in partial portal vein ligated rats.
Reiberger T; Angermayr B; Schwabl P; Rohr-Udilova N; Mitterhauser M; Gangl A; Peck-Radosavljevic M
J Hepatol; 2009 Nov; 51(5):865-73. PubMed ID: 19726100
[TBL] [Abstract][Full Text] [Related]
8. Beneficial effects of dual vascular endothelial growth factor receptor/fibroblast growth factor receptor inhibitor brivanib alaninate in cirrhotic portal hypertensive rats.
Lin HC; Huang YT; Yang YY; Lee PC; Hwang LH; Lee WP; Kuo YJ; Lee KC; Hsieh YC; Liu RS
J Gastroenterol Hepatol; 2014 May; 29(5):1073-82. PubMed ID: 24325631
[TBL] [Abstract][Full Text] [Related]
9. Sorafenib and fluvastatin synergistically alleviate hepatic fibrosis via inhibiting the TGFβ1/Smad3 pathway.
Cheng Y; Zheng H; Wang B; Xu W; Xu J; Zhu Y
Dig Liver Dis; 2018 Apr; 50(4):381-388. PubMed ID: 29373239
[TBL] [Abstract][Full Text] [Related]
10. STAT3-mediated attenuation of CCl4-induced mouse liver fibrosis by the protein kinase inhibitor sorafenib.
Deng YR; Ma HD; Tsuneyama K; Yang W; Wang YH; Lu FT; Liu CH; Liu P; He XS; Diehl AM; Gershwin ME; Lian ZX
J Autoimmun; 2013 Oct; 46():25-34. PubMed ID: 23948302
[TBL] [Abstract][Full Text] [Related]
11. Sorafenib and its derivative SC-1 exhibit antifibrotic effects through signal transducer and activator of transcription 3 inhibition.
Su TH; Shiau CW; Jao P; Liu CH; Liu CJ; Tai WT; Jeng YM; Yang HC; Tseng TC; Huang HP; Cheng HR; Chen PJ; Chen KF; Kao JH; Chen DS
Proc Natl Acad Sci U S A; 2015 Jun; 112(23):7243-8. PubMed ID: 26039995
[TBL] [Abstract][Full Text] [Related]
12. Sorafenib.
Hasskarl J
Recent Results Cancer Res; 2010; 184():61-70. PubMed ID: 20072831
[TBL] [Abstract][Full Text] [Related]
13. Molecular mechanisms of sorafenib action in liver cancer cells.
Cervello M; Bachvarov D; Lampiasi N; Cusimano A; Azzolina A; McCubrey JA; Montalto G
Cell Cycle; 2012 Aug; 11(15):2843-55. PubMed ID: 22801548
[TBL] [Abstract][Full Text] [Related]
14. Reversible decrease of portal venous flow in cirrhotic patients: a positive side effect of sorafenib.
Coriat R; Gouya H; Mir O; Ropert S; Vignaux O; Chaussade S; Sogni P; Pol S; Blanchet B; Legmann P; Goldwasser F
PLoS One; 2011 Feb; 6(2):e16978. PubMed ID: 21340026
[TBL] [Abstract][Full Text] [Related]
15. Sorafenib enhances the antitumor effects of chemoradiation treatment by downregulating ERCC-1 and XRCC-1 DNA repair proteins.
Yadav A; Kumar B; Teknos TN; Kumar P
Mol Cancer Ther; 2011 Jul; 10(7):1241-51. PubMed ID: 21551262
[TBL] [Abstract][Full Text] [Related]
16. Sorafenib protects human optic nerve head astrocytes from light-induced overexpression of vascular endothelial growth factor, platelet-derived growth factor, and placenta growth factor.
Kernt M; Liegl RG; Rueping J; Neubauer AS; Haritoglou C; Lackerbauer CA; Eibl KH; Ulbig MW; Kampik A
Growth Factors; 2010 Jun; 28(3):211-20. PubMed ID: 20166888
[TBL] [Abstract][Full Text] [Related]
17. The STAT3 inhibitor S3I-201 suppresses fibrogenesis and angiogenesis in liver fibrosis.
Wang Z; Li J; Xiao W; Long J; Zhang H
Lab Invest; 2018 Dec; 98(12):1600-1613. PubMed ID: 30206312
[TBL] [Abstract][Full Text] [Related]
18. Sorafenib attenuates p21 in kidney cancer cells and augments cell death in combination with DNA-damaging chemotherapy.
Inoue H; Hwang SH; Wecksler AT; Hammock BD; Weiss RH
Cancer Biol Ther; 2011 Nov; 12(9):827-36. PubMed ID: 21878748
[TBL] [Abstract][Full Text] [Related]
19. Intestinal decontamination inhibits TLR4 dependent fibronectin-mediated cross-talk between stellate cells and endothelial cells in liver fibrosis in mice.
Zhu Q; Zou L; Jagavelu K; Simonetto DA; Huebert RC; Jiang ZD; DuPont HL; Shah VH
J Hepatol; 2012 Apr; 56(4):893-9. PubMed ID: 22173161
[TBL] [Abstract][Full Text] [Related]
20. The effects of sorafenib on liver regeneration in a model of partial hepatectomy.
Kurniali PC; O'Gara K; Wang X; Wang LJ; Somasundar P; Falanga V; Espat NJ; Katz SC
J Surg Res; 2012 Nov; 178(1):242-7. PubMed ID: 22482755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
